Source-grounded facts extracted from Elanco Animal Health Inc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Elanco Animal Health Inc shareholders approved Non-binding approval of compensation of named executive officers at the 2026-05-21 meeting.
“Proposal 3. The shareholders approved, by non-binding vote, the compensation of Elanco’s named executive officers, by the votes set forth in the table below.”
Elanco Animal Health Inc shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for 2026 at the 2026-05-21 meeting.
“Proposal 2. The shareholders ratified the appointment of Ernst & Young LLP as Elanco’s independent registered public accounting firm for 2026, by the votes set forth in the table below.”
Elanco Animal Health Inc shareholders approved Election of Directors at the 2026-05-21 meeting.
“Elanco Animal Health Incorporated (the “Company”) held its annual meeting of shareholders on May 21, 2026. Voting results for each matter submitted to a vote at the 2026 annual meeting are provided below. Proposal 1. Election of Directors.”
Elanco Animal Health Inc reported first quarter of 2026 results: revenue $1,371 million, net income $57 million, EPS $0.11. Guidance raised.
“First Quarter 2026 Results Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target • First Quarter 2026 Financial Results: ◦ Revenue of $1,371 million, an increase of 15% year-o ver-ye ar; 10% organic constant currency growth ◦ Reported Net Income of $57 million, Adjusted Net Income of $204 million ◦ Adjusted EBITDA of $334”
Elanco Animal Health Inc announced a restructuring with charges of approximately $175 million affecting global headcount reduction and closure of Kansas City, Missouri implant facility and exit from portion of Monheim, Germany facility (approximately 300 employees, plus an approximate 300 employees whose positions will be replaced).
“On December 5, 2025, the Board of Directors of Elanco Animal Health Incorporated (the “Company”) authorized a restructuring plan with respect to its workforce (the “Restructuring Plan”) to support margin expansion, optimize the Company’s footprint, and further invest in innovation. The Restructuring Plan will result in a global headcount reduction of approximately 300 employees, plus an approximate 300 employees whose positions will be replaced with positions in growth areas or in lower-cost geographies. Expected pretax charges associated with the Restructuring Plan total approximately $175 million, the majority of which will be incurred in 2025, including an estimated $130 million of cash-based costs, most of which is expected to be paid in the next 2 years, and an estimated $45 million of non-cash asset impairment charges primarily related to the Company’s closure of its Kansas City, Missouri implant facility and exit from a portion of its Monheim, Germany facility.”
Elanco Animal Health Inc incurred term loan of $540,000,000 with JPMorgan Chase Bank, N.A., as administrative agent maturing October 31, 2032.
“providing a new tranche of farm credit term loans in an aggregate principal amount of $540,000,000 with a maturity date of October 31, 2032”
Elanco Animal Health Inc incurred term loan of €400,000,000 with JPMorgan Chase Bank, N.A., as administrative agent maturing April 30, 2029.
“providing a new tranche of euro-denominated senior secured term loans in an aggregate principal amount of €400,000,000 with a maturity date of April 30, 2029”
Elanco Animal Health Inc incurred term loan of $1,100,000,000 with JPMorgan Chase Bank, N.A., as administrative agent maturing October 31, 2032.
“obtaining new U.S. dollar-denominated term loans in an aggregate principal amount equal to $1,100,000,000 with a maturity date of October 31, 2032”
Todd Young changed role as Chief Financial Officer at Elanco Animal Health Inc.
“Mr. VanHimbergen succeeds Todd Young who will continue to serve as an advisor, in a non-executive capacity, through August 31, 2025.”
Robert VanHimbergen was appointed as Executive Vice President and Chief Financial Officer at Elanco Animal Health Inc.
“the Company announced the appointment of Robert (Bob) VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025.”
William F. Doyle resigned as Director at Elanco Animal Health Inc.
“the Company announced certain changes to its Board of Directors, including the decision by William F. Doyle to resign from the Board, effective upon the Company entering into a research agreement”
Stacey Ma was appointed as Director at Elanco Animal Health Inc.
“On November 11, 2024, the Board of Directors (the “Board”) of Elanco Animal Health Incorporated (the “Company”) appointed Stacey Ma, PhD, to the Board”
Elanco Animal Health Inc completed a disposition involving Intervet International B.V. for approximately $1.3 billion in cash (closed 2024-07-09).
“On July 9, 2024, Elanco, Buyer and their applicable affiliates consummated the Transaction. The purchase price was approximately $1.3 billion in cash, subject to customary post-closing adjustments set forth in the Purchase Agreement.”
Elanco Animal Health Inc reported the first quarter of 2024 results: revenue $1,205 million, net income $32 million, EPS $0.06. Guidance reaffirmed.
“Elanco Animal Health Reports First Quarter 2024 Results • First Quarter 2024 Financial Results ◦ Revenue of $1,205 million ◦ Reported Net income of $32 million, Adjusted Net income of $167 million ◦ Adjusted EBITDA of $294 million, or 24.4% of Revenue ◦ Reported EPS of $0.06, Adjusted EPS of $0.34”
Craig Wallace was appointed as Director at Elanco Animal Health Inc.
“On March 29, 2024, Ms. Turner and Mr. Wallace were appointed to the Board.”
Kathy Turner was appointed as Director at Elanco Animal Health Inc.
“On March 29, 2024, Ms. Turner and Mr. Wallace were appointed to the Board.”
Elanco Animal Health Inc reported full year 2024 results: revenue Revenue of $4,450 to $4,540 million, net income Reported Net Loss of $17 to $62 million, EPS Reported EPS of $(0.12) to $(0.03). Guidance initiated.
“Full Year 2024 Guidance: ◦ Revenue of $4,450 to $4,540 million ◦ Reported Net Loss of $17 to $62 million, Adjusted EBITDA of $960 to $1,010 million ◦ Reported EPS of $(0.12) to $(0.03), Adjusted EPS of $0.87 to $0.95”
Elanco Animal Health Inc reported the fiscal year ended December 31, 2023 results: revenue Revenue of $4,417 million, net income Reported Net Loss of $1,231 million, EPS Reported EPS of $(2.50).
“Full Year 2023 Financial Results: ◦ Revenue of $4,417 million ◦ Reported Net Loss of $1,231 million, Adjusted Net Income of $439 million ◦ Adjusted EBITDA of $979 million or 22.2% of Revenue ◦ Reported EPS of $(2.50), Adjusted EPS of $0.89”
Elanco Animal Health Inc reported the fiscal quarter ended December 31, 2023 results: revenue Revenue of $1,035 million, net income Reported Net Loss of $141 million, EPS Reported EPS of $(0.29).
“Fourth Quarter 2023 Financial Results: ◦ Revenue of $1,035 million ◦ Reported Net Loss of $141 million, Adjusted Net Income of $39 million ◦ Adjusted EBITDA of $165 million or 15.9% of Revenue ◦ Reported EPS of $(0.29), Adjusted EPS of $0.08”
Elanco Animal Health Inc announced a restructuring with charges of $50 to $55 million affecting across our global organization (approximately 420 personnel).
“On February 22, 2024, the Board of Directors of Elanco Animal Health Incorporated authorized a restructuring plan with respect to its workforce (the “Restructuring Plan”) to improve operational efficiencies and better align the Company’s organizational structure with current business needs, top strategic priorities and key growth opportunities. The restructuring plan will result in the elimination of approximately 420 personnel across our global organization. Expected pre-tax charges associated with the restructuring plan total $50 to $55 million in 2024, including $40 to $45 million of cash-based severance costs, a majority of which will be paid in 2024.”
Elanco Animal Health Inc entered into Asset Purchase Agreement with Intervet International B.V. valued at approximately $1.3 billion (effective 2024-02-05).
“On February 5, 2024, Elanco Animal Health Incorporated, an Indiana corporation (“Elanco”), and Intervet International B.V., a Dutch private company with limited liability (“Buyer”), entered into an Asset Purchase Agreement (the “Agreement”).”
Elanco Animal Health Inc reported full year 2023 results: revenue Revenue of $4,360 to $4,400 million, net income Reported Net Loss of $1,174 to $1,204 million, EPS Reported diluted EPS of $(2.43) to $(2.37).
“Updating full year 2023 guidance to reflect third quarter outperformance offset by expected unfavorable impact of foreign exchange rates: ◦ Revenue of $4,360 to $4,400 million, constant currency growth improves to flat to 1% ◦ Reported Net Loss of $1,174 to $1,204 million, Reported diluted EPS of $(2.43) to $(2.37) ◦ Adjusted EPS of $0.88 to $0.94, Adjusted EBITDA of $965 to $1,000 million”
Elanco Animal Health Inc reported the fiscal quarter ended September 30, 2023 results: revenue Revenue of $1,068 million, net income Reported Net Loss of $1,096 million, EPS Reported EPS of $(2.22).
“Elanco Animal Health Reports Third Quarter 2023 Results • Third Quarter 2023 Financial Results ◦ Revenue of $1,068 million, representing 4% reported growth or 5% excluding the impact of foreign exchange rates ◦ Reported Net Loss of $1,096 million, inclusive of a non-cash goodwill impairment charge of $1,042 million primarily related to increased long-term treasury rates ◦ Adjusted EBITDA of $214 million, or 20.0% of Revenue ◦ Reported EPS of $(2.22) inclusive of a $(2.10) per share impact of goodwill impairment charge, Adjusted EPS of $0.18”
Elanco Animal Health Inc reported the fiscal quarter ended June 30, 2023 results: revenue $1,057 million, net income $(97) million, EPS $(0.20). Guidance raised.
“or colleen.dekker@elancoah.com Elanco Animal Health Reports Second Quarter 2023 Results and Raises Full Year Guidance · Second Quarter 2023 Financial Results ◦ Revenue of $1,057 million, impacted by an estimated $90-$110 million of revenue related to customer purchasing shifted from the second quarter into the first as a result of ERP system commercial ordering”
Elanco Animal Health Inc incurred credit facility of $300 million with Coöperatieve Rabobank U.A., New York Branch at Term SOFR plus a margin maturing three years.
“guarantor is only of the performance of Elanco US, and not the performance of the Borrower or the debt. The Receivables Securitization Facility (a) has a borrowing capacity of $300 million, (b) has a term of three years, and (c) is subject to customary representations, warranties and indemnification provisions. The interest rate on borrowings under the”
Elanco Animal Health Inc entered into Receivables Loan Agreement with Coöperatieve Rabobank U.A., New York Branch valued at $300 million (effective 2023-08-03).
“On August 3, 2023, Elanco Animal Health Incorporated (the "Company"), solely in its role as performance guarantor, Elanco SPEAR LLC, as Borrower (the "Borrower"), and Elanco US Inc., as servicer ("Elanco US"), entered into a Receivables Loan Agreement dated as of August 3, 2023 with Coöperatieve Rabobank U.A., New York Branch ("Rabobank"), as Administrative Agent, and the lenders from time to time party thereto (the "Agreement"), relating to the company's new accounts receivable securitization facility (the "Receivables Securitization Facility").”
Elanco Animal Health Inc shareholders approved Approval of Amended and Restated 2018 Elanco Animal Health Incorporated Stock Plan.
“Proposal 5. The shareholders approved the Amended and Restated 2018 Elanco Animal Health Incorporated Stock Plan, by the votes set forth in the table below. For Against Abstain Broker Non-Votes 417,966,666 17,058,140 776,360 13,179,219”
Elanco Animal Health Inc shareholders approved Approval of Amended and Restated Elanco Animal Health Incorporated Employee Stock Purchase Plan.
“Proposal 4. The shareholders approved the Amended and Restated Elanco Animal Health Incorporated Employee Stock Purchase Plan, by the votes set forth in the table below. For Against Abstain Broker Non-Votes 434,472,778 566,174 762,214 13,179,219”
Elanco Animal Health Inc shareholders approved Non-binding vote on executive compensation.
“Proposal 3. The shareholders approved, by non-binding vote, the compensation of Elanco’s named executive officers, by the votes set forth in the table below. For Against Abstain Broker Non-Votes 351,081,265 82,468,671 2,251,230 13,179,219”
Elanco Animal Health Inc shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for 2023.
“Proposal 2. The shareholders ratified the appointment of Ernst & Young LLP as Elanco’s independent registered public accounting firm for 2023, by the votes set forth in the table below. For Against Abstain 447,693,969 524,302 762,114”
Elanco Animal Health Inc shareholders approved Election of Directors.
“Proposal 1. Election of Directors. All of the nominees nominated by the Board for director were elected to serve for a three-year term ending at the 2026 annual meeting of shareholders and until their respective successors are elected and qualified, by the votes set forth in the table below. Nominee For Against Abstain Broker Non-Votes Michael J. Harrington 259,613,361 175,243,353 944,452 13,179,219 R. David Hoover 125,220,272 309,651,471 929,423 13,179,219 Deborah T. Kochevar 164,946,577 269,918,338 936,251 13,179,219 Kirk P. McDonald 267,112,564 167,731,710 956,892 13,179,219”
Elanco Animal Health Inc reported financial results for the fiscal quarter ended March 31, 2022.
“Attached as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated May 9, 2023, announcing the results of operations for the fiscal quarter ended March 31, 2022 and guidance for the full year, first half and second quarter of 2023, for Elanco Animal Health Incorporated.”
Elanco Animal Health Inc reported the full year ended December 31, 2022 results: revenue $4,411 million, net income $(78) million, EPS $(0.16).
“Full year 2022: o Revenue decreased from $4,418 million to $4,411 million o Reported net loss increased from $74 million to $78 million, adjusted net income decreased from $548 million to $544 million o Adjusted EBITDA decreased from $1,023 million to $1,017 million o Reported EPS decreased from $(0.15) to $(0.16), Adjusted EPS was unchanged”
Elanco Animal Health Inc reported the fiscal quarter ended December 31, 2022 results: revenue $985 million, net income $(55) million, EPS $(0.11).
“Fourth quarter of 2022: o Revenue decreased from $988 million to $985 million o Reported net loss increased from $54 million to $55 million, adjusted net income decreased from $95 million to $94 million o Adjusted EBITDA decreased from $174 million to $172 million o Reported and adjusted EPS was unchanged”
Elanco Animal Health Inc updated its the full year and fiscal quarter ended December 31, 2022 guidance (initiated).
“Attached as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated February 21, 2023, announcing the results of operations for the full year and fiscal quarter ended December 31, 2022 and guidance for the full year and first half of 2023”
Elanco Animal Health Inc reported the fiscal quarter ended September 30, 2022 results: revenue $1,028 million, net income Reported Net Loss of $49 million, EPS Reported EPS of $(0.10). Guidance lowered.
“Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Reports Third Quarter 2022 Results • Third Quarter 2022 Financial Results ◦ Revenue of $1,028 million ◦ Reported Net Loss of $49 million, Adjusted Net Income of $96 million ◦ Adjusted EBITDA of $205 million or 19.9% of Revenue ◦ Reported EPS of $(0.10), Adjusted EPS of $0.20 ◦”
Scott D. Ferguson departed as Director at Elanco Animal Health Inc.
“Scott D. Ferguson, a member of the Board of Directors (the “Board”) of the Company and founder and managing partner of Sachem Head Capital Management (“Sachem Head”), an investor in the Company, has stepped down from the Board, effective September 7, 2022, in connection with Mr. Ferguson and Sachem Head refocusing his time across other Sachem Head Board commitments.”
Aaron Schacht departed as Executive Vice President at Elanco Animal Health Inc.
“On December 31, 2021, Mr. Schacht, and certain other employees supporting the Microbiome Platform, separated from Elanco as part of the restructuring plan announced by Elanco on November 30, 2021.”
Aaron Schacht changed role as Executive Vice President of Innovation, Regulatory, and Business Development at Elanco Animal Health Inc.
“Aaron Schacht, Elanco’s Executive Vice President of Innovation, Regulatory, and Business Development, is transitioning to lead the potential carve-out of Elanco’s microbiome R&D platform”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.